Children's Medical Center Corporation

Intrexon Corporation

Glycomimetics, Inc.

Entremed, Inc.

Precigen, Inc.

Casi Pharmaceuticals, Inc.

William E Fogler

John L Magnani

Jamshed H Shah

Shawn J Green

Adonia E Papathanassiu

Sunil D Chada

John W Madsen

Charles C Reed

Brandon Cuthbertson

Jeremiah F Roeth

Robert J D'Amato

Glenn M Swartz, Jr

Stacy Plum

Glenn M Swartz

Fayaz Khazi

Carolyn F Sidor

Sunil Chada

Stacy M Plum

Methods are disclosed for the mobilization of marrow infiltrating cells (MILs) using E-selectin antagonists for the treatment of disorders such as cancer. Methods for treating or preventing cancers using MILs mobilized by E-selectin antagonists are further disclosed.

Methods of mobilizing marrow infiltrating lymphocytes and uses thereof

Compositions and methods for the treatment of diseases, disorders, and/or conditions associated with the increased regulatory T lymphocyte cell function, comprising the administration of T-cell checkpoint inhibitors in combination with E-selectin inhibitors, C&#x2014;X&#x2014;C Motif Chemokine Receptor 4 (CXCR4) receptor inhibitors, and/or heterobifunctional inhibitors that comprise at least one E-selectin inhibitor linked to at least one CXCR4 receptor inhibitor, are disclosed.

Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4

This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.

Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof

This invention relates to the field of therapeutics. Disclosed are methods of conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.

Vectors conditionally expressing protein

The present invention relates a composition for treating rheumatic diseases. The composition comprises a compound having the formula wherein Ris selected from &#x2014;OCH, &#x2014;OCHCH, &#x2014;CH, &#x2014;CHCH, &#x2014;CCCH, &#x2014;CHCH&#x2014;CH, or CH&#x2014;CHCH; and one or more anti-rheumatic agents. A method of using the composition for treating rheumatic diseases in humans and animals is also disclosed.

Disease modifying anti-arthritic activity of 2-methoxyestradiol

The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(&#x2212;)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

Methods of treating undesired angiogenesis with 2-methyl-EM-138

The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(&plus;)-2-methyl-2-phthalimidinoglutaric acid and (S)-(&minus;)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.

Analogs of 2-Phthalimidinoglutaric acid

Growing community of inventors

Rockville, MD, United States of America

William E Fogler